Anbio Biotechnology Cl A NNNN

$3.20 +0.07 (2.24%)

Valuation

Market cap
450,379,000
Revenue TTM
$8,650,000
Net income TTM
$6,400,000
PE ratio
0.00
Forward PE
—
Profit margin
73.99%
Debt to equity
0.00

Trading

Volume
28,116
Avg volume
176,778
Day's range
$3.20 – $3.45
Shares out
143,891,000
Stochastic %K
2%
Beta
5.31
Analysts
Strong Buy
Price target
—

Price

Company profile

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen r...

Show more

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

Industry
Medical Instruments & Supplies
Sector
Healthcare
Phone
49 698 7003 9170
Website
https://www.anbiobiotechnology.com
Address
Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, Germany

Latest news